Literature DB >> 12454749

Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells.

Z Zheng1, S Venkatapathy, G Rao, C A Harrington.   

Abstract

We used oligonucleotide microarrays to profile the expression of chronic lymphocytic leukemia (CLL) B cells from eight patients compared with CD5-expressing normal B cells from four donors and with pooled normal circulating B cells. Of 6790 genes examined, we identified 87 genes that were differentially expressed at least two-fold between CLL and the normal B cells. CLL cells significantly down-regulated transcripts from CD1c and CD1d genes, which encode proteins known to present lipid antigen and mediate innate and adaptive immunity. The expression pattern was also consistent with reduced signaling by interferon gamma but increased response to interleukin 4 in leukemic cells. CLL cells increased the expression of several collagen-associated extracellular matrix and adhesion molecules, up-regulated many genes involved in intracellular protein transport and processing, while downregulating genes involved in proliferation and metabolism. Based on the expression pattern, we propose that CLL-B cells prolong their survival through increased interaction with survival factors such as IL-4, and through various mechanisms of evading the immune response, such as turning off the expression of CD1c and CD1d, reducing immunogenic response to interferon gamma, inactivating T cell in B-T interaction and increasing the expression of immunoglobulin receptors which neutralize antibody-dependent cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454749     DOI: 10.1038/sj.leu.2402711

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

Review 1.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

2.  Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Authors:  Hui Zhi Low; Dorothee Hilbrans; Ingo G H Schmidt-Wolf; Harald Illges
Journal:  Int J Hematol       Date:  2012-08-17       Impact factor: 2.490

3.  The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.

Authors:  Lela Kardava; Qi Yang; Anthony St Leger; Kenneth A Foon; Suzanne Lentzsch; Abbe N Vallejo; Christine Milcarek; Lisa Borghesi
Journal:  Int Immunol       Date:  2011-05-06       Impact factor: 4.823

4.  Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.

Authors:  Robert Weinkove; Collin R Brooks; John M Carter; Ian F Hermans; Franca Ronchese
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.

Authors:  Chunyan Zhang; Hong Xin; Wang Zhang; Paul J Yazaki; Zhifang Zhang; Keith Le; Wenzhao Li; Heehyoung Lee; Larry Kwak; Stephen Forman; Richard Jove; Hua Yu
Journal:  Immunity       Date:  2016-04-19       Impact factor: 31.745

6.  Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems.

Authors:  Sapan J Patel; Su Dao; Costel C Darie; Bayard D Clarkson
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

Review 7.  Invariant natural killer T cells balance B cell immunity.

Authors:  Elizabeth A Leadbetter; Mikael C I Karlsson
Journal:  Immunol Rev       Date:  2021-01-12       Impact factor: 12.988

8.  A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Lixia Diao; Rachel J Newman; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; Rajyalakshmi Luthra; L Jeffrey Medeiros; Michael J Keating; Lynne V Abruzzo
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

9.  ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro.

Authors:  Sarah Weiler; Jolaolu A Ademokun; John D Norton
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

10.  Occurrence of nodular lymphocyte-predominant hodgkin lymphoma in hermansky-pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects.

Authors:  Luisa Lorenzi; Giovanna Tabellini; William Vermi; Daniele Moratto; Fulvio Porta; Lucia D Notarangelo; Ornella Patrizi; Silvano Sozzani; Genevieve de Saint Basile; Sylvain Latour; David Pace; Silvia Lonardi; Fabio Facchetti; Raffaele Badolato; Silvia Parolini
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.